𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety and tolerance of recombinant interferon alfa-2a (roferon®-A) in Cancer Patients

✍ Scribed by Gary J. Jones; Loretta M. Itri

Publisher
John Wiley and Sons
Year
1986
Tongue
English
Weight
748 KB
Volume
57
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical studies of recombinant interfer
Clinical studies of recombinant interferon alfa-2a (Roferon®-A) in cancer patients
✍ Tetsuo Taguchi 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 345 KB 👁 2 views

A Phase I study of interferon alfa-2a was conducted in 20 patients with disseminated cancer to establish the relationship between dose and interferon-related side effects. Fever was the most common side effect, and was not doserelated. Other side effects not related to dose included flu-like symptom

Management of cancer patients receiving
Management of cancer patients receiving interferon alfa-2a
✍ L. Gauci 📂 Article 📅 1987 🏛 John Wiley and Sons 🌐 French ⚖ 652 KB

This is a review of the data on the safety and tolerance of interferon alfa-2a in the treatment of cancer patients and is particularly aimed at patient care. Since 1981, interferon alfa-2a prepared from human sources has been administered t o over 2500 cancer patients and 2500 patients with viral di

A phase I study of subcutaneous recombin
A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a
✍ Mark J. Ratain; Edwin R. Priest; Linda Janisch; Nicholas J. Vogelzang 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 495 KB 👁 2 views

Background. Both recombinant in1 erferon alfa and interleukin-2 (IL-2) have been shown to lave some activity as single agents in metastatic renal cj !I1 cancer (RCC), although their activity is minimal in mo -e common solid tumors. Recent preclinical studies hav ? suggested that the combination of t